Is it equivalent? Evaluation of the clinical activity of single agent Lipodox(R) compared to single agent Doxil(R) in ovarian cancer treatment

Conclusion
Lipodox® for treatment of recurrent ovarian cancer did not appear to have equivalent efficacy compared to Doxil®. A prospective clinical study is warranted before Lipodox® can be deemed equivalent substitution for Doxil®.

Source: Journal of Oncology Pharmacy Practice - June 20, 2016 Category: Cancer & Oncology Authors: Smith, J. A., Costales, A. B., Jaffari, M., Urbauer, D. L., Frumovitz, M., Kutac, C. K., Tran, H., Coleman, R. L. Tags: Original Articles Source Type: research